155899-34-6

Basic information

• Product Name: 2(R)-Propyl-4-hexynoic acid
• Synonyms: ABS-103R; R-ABS-103; R-103
• CAS NO: 155899-34-6
• Molecular Formula: C₉H₁₄O₂
• Molecular Weight: 154.21073
• Mol File: 155899-34-6.mol

Chemical Properties

• CAS DataBase Reference: 2(R)-Propyl-4-hexynoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2(R)-Propyl-4-hexynoic acid(155899-34-6)
• EPA Substance Registry System: 2(R)-Propyl-4-hexynoic acid(155899-34-6)

Safety Data

• Hazardous Substances Data: 155899-34-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2(R)-Propyl-4-hexynoic acid is utilized as a key intermediate in the synthesis of a variety of drugs. Its chemical structure allows for the creation of complex molecules that can be tailored for specific therapeutic applications, making it an essential component in drug development.
Used in Flavor and Fragrance Industry:
2(R)-Propyl-4-hexynoic acid is employed in the production of flavors and fragrances, where its unique chemical properties contribute to the creation of distinct scents and tastes. Its versatility in this industry is attributed to its ability to form a wide range of aromatic compounds.
Used in Organic Synthesis:
2(R)-Propyl-4-hexynoic acid is used in the synthesis of organic compounds, where its carboxylic acid and alkyne groups can be manipulated to produce a diverse array of chemical products. This makes it a valuable building block in the field of organic chemistry, with applications in research and commercial production.

Upstream product

• 2163-48-6 diethyl propylmalonate 
• 3355-28-0 1-Bromo-2-butyne 

Relevant articles and documents

Anticonvulsant and neurotoxic activities of twelve analogues of valproic acid.

Twelve racemic analogues of the antiepileptic drug valproic acid (VPA) were tested and compared with VPA for anticonvulsant activity by the subcutaneous pentylenetetrazol (PTZ) seizure threshold test and for neurotoxicity by the rotorod test. Four compounds produced maximal anticonvulsant activity (100% protection) in equimolar doses (1.5 mmol/kg) to VPA and two compounds showed a similar effect with lower doses (1.0 mmol/kg). Four compounds produced lower activity (38-80% protection), and two compounds showed no anticonvulsant activity at the dose used (1.5 mmol/kg). Two of the 12 compounds, (+/-)-2-n-propyl-4-hexynoic acid (11) and (+/-)-4-methyl-2-n-propyl-4-pentenoic acid (12), showed no sedation at doses that produced the maximum anticonvulsant effect. For the first time we succeeded to develop two compounds with higher protective index and safety ratios than VPA. Compound 11 had a longer duration of action and higher protective index but a lower safety ratio than 12. Comparisons of the anticonvulsant and minimal neurotoxic effects of these compounds with their calculated lipophilicity (C log P) revealed that compounds with the desired high anticonvulsant activity and minimal neurotoxicity showed C log P values between 1.84 and 2.64 and had nine carbon atoms (in contrast to eight carbon atoms for VPA).